Recombinant Human MAGEA5 protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MAGEA5 also known as Melanoma Antigen Family A5 is a protein with a molecular mass of approximately 35 kDa. It belongs to the MAGE family which is characterized by shared sequence homologies. MAGEA5 expression occurs in a limited range of normal tissues typically restricted to testis but is often found overexpressed in various types of tumors. This pattern makes it a commonly studied target in cancer research marking its significance in areas related to tumor biology.

Biological function summary

MAGEA5 contributes to the regulation of cellular processes such as apoptosis and cell cycle progression. It functions as part of a larger protein complex involving other MAGE family members often altering cellular stress responses. By interacting with other proteins involved in cell survival MAGEA5 can modify how cells respond to external stimuli potentially influencing cancer cell proliferation and survival.

Pathways

Several intricate molecular processes involve MAGEA5 including apoptosis and cell cycle regulation pathways. It intersects with proteins like p53 and pRb known for their roles in controlling cell growth and death. Through its interactions MAGEA5 might influence how p53 pathways modulate stress-induced apoptosis and how pRb involvement affects cell cycle checkpoints. These associations highlight MAGEA5’s role in tumorigenic processes through modification of these critical signaling networks.

Research links MAGEA5 to cancer especially melanoma and lung cancer. Overexpression of MAGEA5 is observed in tumor cells often correlating with a more aggressive tumor phenotype further implicating it in cancerous pathologies. MAGEA5 also associates with proteins such as NY-ESO-1 another cancer-testis antigen involved in tumorigenesis. The connection with these proteins suggests MAGEA5 might serve as a potential biomarker or therapeutic target aiding in the development of cancer immunotherapies.